Taking Stock of Current and Emerging Anti-VEGF Therapy Dosing Regimens for nAMD

Program Overview

Neovascular age-related macular degeneration (nAMD) is among the leading causes of blindness worldwide. Although the availability of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have shifted the care paradigm for nAMD, the need for frequent injections is a major contributor to the burden of this disease. Consequently, newer treatment strategies that simplify patient care, improve patient satisfaction, increase treatment compliance, and lower the burden of nAMD have been highly sought after.

In this CME activity, 2 leading retina specialists analyze key data on approved and emerging anti-VEGF therapies for nAMD, focusing on the implications of newer agents and dosing regimens on easing the burden of treatment associated with this disease.

0.5 CE Credit(s)
Expires: July 30, 2024

Target Audience

Ophthalmology, retina specialists, and optometry clinicians 

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the burden patients with neovascular age-related macular degeneration (nAMD) encounter over the course of their disease
  • Assess the benefits and limitations of conventional intravitreal therapies and dosing strategies for the management of nAMD
  • Identify the potential implications of recent data on novel and emerging treatment strategies on the management of nAMD

Activity Faculty

78-23-1288-VL-002 AMD-Faculty Headshot-Brown

David M. Brown, MD, FACS

Clinical Professor, Ophthalmology
Cullen Eye Institute, Baylor College of Medicine
Vice Chair, Research
Blanton Eye Institute, Houston Methodist Hospital
Director, Research
Retina Consultants of Texas
San Antonio, TX

78-23-1288-VL-002 AMD-Faculty Headshot-Schneide

Eric W. Schneider, MD, FASRS

Retina Specialist, Ophthalmology Clinic
Tennessee Retina
Nashville, TN

Educational Resources


Supporter Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.  

Provider Statement

Provided by RMEI Medical Education, LLC

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. 


David M. Brown, MD, FACS, has relevant financial relationships with 4D Molecular Therapeutics, Inc., Adverum Biotechnologies Inc., AGTC, Alexion Pharmaceuticals Inc., Annexon Inc., Apellis Pharmaceuticals Inc., Bayer AG, Biogen MA Inc., Boehringer Ingelheim, Celltrion Healthcare Co., Ltd., Chengdu Kanghong Pharmaceutical Industry Group Co., Ltd., Clearside Biomedical Inc., Coherus BioScience Inc., Gemini Therapeutics Inc., Glaukos Inc., Heidelberg Engineering, Inc., IVERIC bio, inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Molecular Partners AG, Novartis Pharma AG, Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., Optos plc, Pontifax, PPD, Inc., Ray Therapeutics Inc., Regeneron Pharmaceuticals Inc., RetinAI Medical AG, Samsungbioepis Co,Ltd., SciNeuro Therapeutics Inc., Senju Pharmaceutical Co., Ltd., Shanghai SIMR Biotechnology Co., Ltd., Smilebiotek Zhuhai Limited, Stealth BioTherapeutics Inc., Verseon International Corporation (Consultant); Adverum Biotechnologies, Inc., Aldeyra Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Alimera Sciences Inc., Alkahest, Inc., Amgen Inc., Annexon, Inc, Apellis Pharmaceuticals, Inc., Aura Sub, LLC, Bayer AG, Boehringer Ingelheim,  Carl Zeiss Meditec AG, Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Gemini Therapeutics Inc., Genentech/Roche, Graybug Vision, Inc., Gyroscope, Ionis Pharmaceuticals, Inc., Irenix Medical, Inc., IVERIC bio, inc., Kodiak Sciences, LumiThera, Inc., nanoscope therapeutics inc., NEINH, Neurotech Services Ltd., NGM Biopharmaceuticals Inc., Novartis Pharma AG, Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., Opthea Limited, Opthotech Corporation, Optos plc, Oxurion NV, Oyster Point Pharma, Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc., Roche, Sam Chun Dang Pharm. Co., LTD., Samsung, Sandoz Inc., Senju, Santen Pharmaceutical Co., Ltd., Stealth, Unity, Xbrane Biopharma (Grant/Research Support); Adverum Biotechnologies, Inc., Clearside Biomedical Inc. (Stock/Shareholder). 

Eric W. Schneider, MD, FASRS, has relevant financial relationships with Carl Zeiss Meditec AG, Notal Vision, Inc. (Consultant); 4D Molecular Therapeutics, Inc., Adverum Biotechnologies, Inc., AffaMed Therapeutics, Apellis Pharmaceuticals, Astellas Pharma Inc., Chengdu Kanghong Biotechnology Ltd., EyePoint Pharmaceuticals, Genentech Inc., Ionis Pharmaceuticals, Inc., Kodiak Sciences, Mylan N.V., NGM Biopharmaceuticals Inc., Notal Vision, Inc., Novartis, OcuTerra Therapeutics, Opthea, Oxurion NV, Priovant Therapeutics, Regeneron Pharmaceuticals Inc., REGENXBIO Inc. (Grant/Research Support). 

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies. 

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose. 

Joint Accreditation Statement 

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Credit Designation

Physician Continuing Medical Education 
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

COPE Credit Hours 
RMEI Medical Education, LLC designates this Asynchronous Online activity for a maximum of 0.5 COPE credit hour(s). Optometrists should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]. 

Users must: 

  • Read the learning objectives and faculty disclosures 
  • Participate in the activity 
  • Complete the activity evaluation

There is no fee to participate. 



*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources